MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint
The Siglecs (sialic acid-binding immunoglobulin-like lectins) are glycoimmune checkpoint receptors that suppress immune cell activation upon engagement of cognate sialoglycan ligands. The cellular drivers underlying Siglec ligand production on cancer cells are poorly understood. We find the MYC oncogene causally regulates Siglec ligand production to enable tumor immune evasion. A combination of glycomics and RNA-sequencing of mouse tumors revealed the MYC oncogene controls expression of the sialyltransferase St6galnac4 and induces a glycan known as disialyl-T. Using in vivo models and primary human leukemias, we find that disialyl-T functions as a "don't eat me" signal by engaging macrophage Siglec-E in mice or the human ortholog Siglec-7, thereby preventing cancer cell clearance. Combined high expression of MYC and ST6GALNAC4 identifies patients with high-risk cancers and reduced tumor myeloid infiltration. MYC therefore regulates glycosylation to enable tumor immune evasion. We conclude that disialyl-T is a glycoimmune checkpoint ligand. Thus, disialyl-T is a candidate for antibody-based checkpoint blockade, and the disialyl-T synthase ST6GALNAC4 is a potential enzyme target for small molecule-mediated immune therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:120 |
|---|---|
| Enthalten in: |
Proceedings of the National Academy of Sciences of the United States of America - 120(2023), 11 vom: 14. März, Seite e2215376120 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Smith, Benjamin A H [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 21.03.2023 Date Revised 02.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1073/pnas.2215376120 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354036661 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354036661 | ||
| 003 | DE-627 | ||
| 005 | 20231226061346.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1073/pnas.2215376120 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1180.xml |
| 035 | |a (DE-627)NLM354036661 | ||
| 035 | |a (NLM)36897988 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Smith, Benjamin A H |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.03.2023 | ||
| 500 | |a Date Revised 02.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The Siglecs (sialic acid-binding immunoglobulin-like lectins) are glycoimmune checkpoint receptors that suppress immune cell activation upon engagement of cognate sialoglycan ligands. The cellular drivers underlying Siglec ligand production on cancer cells are poorly understood. We find the MYC oncogene causally regulates Siglec ligand production to enable tumor immune evasion. A combination of glycomics and RNA-sequencing of mouse tumors revealed the MYC oncogene controls expression of the sialyltransferase St6galnac4 and induces a glycan known as disialyl-T. Using in vivo models and primary human leukemias, we find that disialyl-T functions as a "don't eat me" signal by engaging macrophage Siglec-E in mice or the human ortholog Siglec-7, thereby preventing cancer cell clearance. Combined high expression of MYC and ST6GALNAC4 identifies patients with high-risk cancers and reduced tumor myeloid infiltration. MYC therefore regulates glycosylation to enable tumor immune evasion. We conclude that disialyl-T is a glycoimmune checkpoint ligand. Thus, disialyl-T is a candidate for antibody-based checkpoint blockade, and the disialyl-T synthase ST6GALNAC4 is a potential enzyme target for small molecule-mediated immune therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a MYC | |
| 650 | 4 | |a Siglec | |
| 650 | 4 | |a glycosylation | |
| 650 | 4 | |a oncogene | |
| 650 | 7 | |a Antigens, CD |2 NLM | |
| 650 | 7 | |a Ligands |2 NLM | |
| 650 | 7 | |a Sialic Acid Binding Immunoglobulin-like Lectins |2 NLM | |
| 650 | 7 | |a Myc protein, mouse |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins c-myc |2 NLM | |
| 700 | 1 | |a Deutzmann, Anja |e verfasserin |4 aut | |
| 700 | 1 | |a Correa, Kristina M |e verfasserin |4 aut | |
| 700 | 1 | |a Delaveris, Corleone S |e verfasserin |4 aut | |
| 700 | 1 | |a Dhanasekaran, Renumathy |e verfasserin |4 aut | |
| 700 | 1 | |a Dove, Christopher G |e verfasserin |4 aut | |
| 700 | 1 | |a Sullivan, Delaney K |e verfasserin |4 aut | |
| 700 | 1 | |a Wisnovsky, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Stark, Jessica C |e verfasserin |4 aut | |
| 700 | 1 | |a Pluvinage, John V |e verfasserin |4 aut | |
| 700 | 1 | |a Swaminathan, Srividya |e verfasserin |4 aut | |
| 700 | 1 | |a Riley, Nicholas M |e verfasserin |4 aut | |
| 700 | 1 | |a Rajan, Anand |e verfasserin |4 aut | |
| 700 | 1 | |a Majeti, Ravindra |e verfasserin |4 aut | |
| 700 | 1 | |a Felsher, Dean W |e verfasserin |4 aut | |
| 700 | 1 | |a Bertozzi, Carolyn R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Proceedings of the National Academy of Sciences of the United States of America |d 1915 |g 120(2023), 11 vom: 14. März, Seite e2215376120 |w (DE-627)NLM000008982 |x 1091-6490 |7 nnns |
| 773 | 1 | 8 | |g volume:120 |g year:2023 |g number:11 |g day:14 |g month:03 |g pages:e2215376120 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1073/pnas.2215376120 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 120 |j 2023 |e 11 |b 14 |c 03 |h e2215376120 | ||